AbCellera Biologics

ABCL51

Penny Stock

$2.62arrow_drop_down4.71%-$0.12

Penny Stock

ABCL51

$2.62

arrow_drop_down4.71%-$0.12

Penny Stock

Performance History

Key Stats
Open	$3.14
Prev. Close	$3.15
EPS	-0.61
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$930.40M
PE Ratio	-

	LOW	HIGH
Day Range	3.08	3.17
52 Week Range	2.33	6.05

Ratios







EPS	-0.61

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About AbCellera Biologics (ABCL)

AbCellera Biologics Inc. (ABCL) is a leading biotechnology company that specializes in the discovery and development of therapeutic antibodies. The company uses its innovative platform to identify and analyze natural immune responses to disease, enabling the rapid generation of high-quality antibody candidates. AbCellera has a strong track record of success, with several antibody candidates currently in clinical trials across a range of indications. The company's proprietary technology and extensive expertise in antibody discovery have positioned it as a leader in the field.

The stock price history of AbCellera Biologics Inc. (ABCL) has shown strong growth since the company's initial public offering (IPO) in December 2020. In just a few months, the stock has more than doubled in value, reflecting the market's confidence in the company's potential. The company's positive financial performance and promising pipeline of antibody candidates have contributed to investor enthusiasm. Analysts are optimistic about AbCellera's future prospects, citing its strong partnerships with leading pharmaceutical companies and its ability to leverage its technology in multiple therapeutic areas.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Carl L.G. Hansen Ph.D.
Headquarters: Vancouver
Employees: 590
Exchange: NASDAQ

Keep an eye on AbCellera Biologics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is AbCellera Biologics 's (ABCL) price per share?

The current price per share for AbCellera Biologics (ABCL) is $2.62. The stock has seen a price change of -$0.13 recently, indicating a -4.71% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for AbCellera Biologics (ABCL)?

For AbCellera Biologics (ABCL), the 52-week high is $6.06, which is 130.67% from the current price. The 52-week low is $2.34, the current price is 12.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is AbCellera Biologics (ABCL) a growth stock?

AbCellera Biologics (ABCL) has shown an average price growth of -4.94% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying AbCellera Biologics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is AbCellera Biologics (ABCL) stock price performance year to date (YTD)?

As of the latest data, AbCellera Biologics (ABCL) has a year-to-date price change of -54.19%. Over the past month, the stock has experienced a price change of 4.17%. Over the last three months, the change has been 0.19%. Over the past six months, the figure is -31.28%.

help

Is AbCellera Biologics (ABCL) a profitable company?

AbCellera Biologics (ABCL) has a net income of -$146.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 18.75% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.44K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $38.02M, although specific revenue growth data is currently not available. The gross profit is $7.13M. Operating income is noted at -$237.21M. Furthermore, the EBITDA is -$222.24M.

help

What is the market capitalization of AbCellera Biologics (ABCL)?

AbCellera Biologics (ABCL) has a market capitalization of $815.21M. The average daily trading volume is 2.66, indicating the stock's liquidity and investor engagement.